The Significance of VEGF Expression in Stage II Carcinoma of Uterine Cervix Treated with Definitive Radiotherapy.
- Author:
Won PARK
1
;
Yoon La CHOI
;
Seung Jae HUH
;
Sang Min YOON
;
Young Je PARK
;
Hee Rim NAM
;
Yong Chan AHN
;
Do Hoon LIM
;
Hee Chul PARK
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonro.park@samsung.com
- Publication Type:Original Article
- Keywords:
Cervix cancer;
VEGF;
Prognostic factor
- MeSH:
Brachytherapy;
Cervix Uteri*;
Disease-Free Survival;
Female;
Follow-Up Studies;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Paraffin;
Particle Accelerators;
Pelvis;
Prognosis;
Radiotherapy*;
Recurrence;
Uterine Cervical Neoplasms;
Vascular Endothelial Growth Factor A*
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2006;24(1):37-43
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We wanted to determine the clinical characteristics and prognosis according to the VEGF expression in stage II cervical carcinoma patients treated with definitive radiotherapy. MATERIALS AND METHODS: We enrolled 31 patients who were diagnosed with cervical cancer from 1995 to 2003 at Samsung Medical Center and their paraffin block tissue samples were available for study. The median age of the patients was 65 years. The mean tumor size was 4.1 cm (range: 1.2~8.2 cm). Seven patients (22.6%) were suspected of having pelvic lymph node metastasis. An external beam irradiation dose of 45-56.4 Gy was administered to the whole pelvis with a 15 MV linear accelerator, and an additional 24 Gy was given to point A by HDR intracavitary brachytherapy. VEGF staining was defined as positive when more than 10% of the tumor cells were stained. The median follow-up duration was 58 months. RESULTS: A positive VEGF expression was observed in 21 patients (67.7%). There was no significant correlation between the VEGF expression and pelvic lymph node metastasis, tumor size and the response of radiotherapy. During follow-up, 7 patients had recurrence. The complete response rate was not significant between the VEGF (-) and VEGF (+) tumors. However, the VEGF (+) tumors showed a significantly higher recurrence rate in comparison with the VEGF (-) tumors (p=0.040). The three year disease-free survival rates were 100% and 66.7%, respectively, for patients with VEGF (-) or VEGF (+) tumor (p=0.047). CONCLUSION: The VEGF expression was a significant factor for recurrence and disease-free survival. However, the significance of the VEGF expression is still controversial because of the various definitions of VEGF expression and the mismatches of the clinical data in the previous studies.
